PD-L1 CAR-T cells (Sun Yat-sen University)

This is an investigational autologous chimeric antigen receptor T (CAR-T) cell therapy developed by Sun Yat-sen University for the treatment of advanced non-small cell lung cancer (NSCLC). The patient's own T cells are genetically modified using a lentiviral vector to express a CAR comprising a PD-L1-specific single-chain variable fragment (scFv) derived from a monoclonal antibody, linked to intracellular signaling domains including CD3 zeta and costimulatory molecules CD137 (4-1BB) and CD28. This modification allows the T cells to specifically recognize and eliminate tumor cells expressing Programmed death-ligand 1 (PD-L1). The therapy is currently being evaluated in Phase I clinical trials focusing on safety, toxicity, and preliminary efficacy in NSCLC patients who have failed standard treatments and show positive PD-L1 expression.

Other names

PD-L1-targeting autologous chimeric antigen receptor T cellsPD-L-1-targeting autologous chimeric antigen receptor T cellsPD-L 1-targeting autologous chimeric antigen receptor T cellsPD-L1-specific CAR-T cellsPD-L-1-specific CAR-T cellsPD-L 1-specific CAR-T cellsPD-L1 CAR-TPD-L-1 CAR-TPD-L 1 CAR-T